Compare

Protagonist Therapeutics/$PTGX

1D1W1M3M6MYTD1Y5YMAX

About Protagonist Therapeutics

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Ticker
$PTGX
Sector
Health
Primary listing
NASDAQ
Employees
149

PTGX Metrics

BasicAdvanced
$8.1B
25.17
$4.93
1.22
-

What the Analysts think about PTGX

Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
Analyst projections of the future price of Protagonist Therapeutics stock.

Bulls say / Bears say

Rusfertide (MIMRYLO) has progressed from a successful Phase 3 trial to FDA approval: 76.9% of patients responded, versus 32.9% on placebo, and the trial also showed improved fatigue. Approval triggered $275 million in payments, with 14%–29% royalties on future worldwide sales. (Newswire, U.S. Securities and Exchange Commission)
Icotrokinra is approved in the US, EU, Japan and China, and is being tested in Phase 3 for further immune diseases, including psoriatic arthritis, ulcerative colitis and Crohn’s disease. Those uses could add to PTGX’s 6%–10% royalties and up to $580 million in potential milestones from J&J. (U.S. Securities and Exchange Commission)
PTGX had $834.6 million in cash, equivalents and marketable securities at 30 September, giving it resources to advance its own pipeline. Its oral IL-17 candidate PN-881 showed Phase 1 drug levels above targeted thresholds, with a Phase 2b psoriasis study planned for early 2027. (U.S. Securities and Exchange Commission)
Third-quarter net income was $220 million, but $266.6 million of the quarter’s $274.4 million collaboration revenue came from recognition of Takeda opt-out and approval payments. That makes the reported profit a poor guide to recurring earnings from product sales. (U.S. Securities and Exchange Commission)
PTGX does not control the commercial effort behind either approved drug: Takeda has exclusive worldwide rights to MIMRYLO, while J&J handles ICOTYDE’s development and sales. Future royalties and milestones therefore depend on partners’ launch execution and the medicines’ uptake. (U.S. Securities and Exchange Commission)
In a Phase 3 psoriasis comparison, icotrokinra was non-inferior to ustekinumab but did not show statistical superiority. That may make it harder to stand out against established treatments and win market share. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 13 Nov 2026.

PTGX Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

PTGX Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.